EOEkaterina P. Omelchuk

Ekaterina P. Omelchuk

*This is an algorithmically generated author record based on publicly available information.

Ekaterina P. Omelchuk has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A novel minimally invasive diagnostic approach of various brain malignancies based on differential miRNA expression

    by Dmitry Yu. Gvaldin, Natalia A. Petrusenko, Ekaterina P. Omelchuk, Natalya N. Timoshkina, Moez Eid, Dema Alset, Eduard E. Rostorguev, Sergey E. Kavitskiy, Oleg I. Kit

  • Open Access

    Search for diagnostic microRNAs for brain tumor identification using a low-temperature plasma bank

    by O. I. Kit, N. N. Timoshkina, E. P. Omelchuk, D. Yu. Gvaldin, N. A. Petrusenko, I. A. Novikova, E. E. Rostorguev

    Aim . To assess the level of circulating small non-coding ribonucleic acids (microRNAs), previously identified as differentially expressed in next-generation sequencing (NGS) profiles of various brain tumor types, using a validation cohort formed from a low-temperature plasma bank. Material and methods . Plasma bioarchiving was performed on pa­tients treated for brain tumors at the National Medical Research Center of Oncology from April 2018 to December 2024. Reverse transcription-­polymerase chain reaction (RT-PCR) was used to determine the levels of 10 microRNAs in plasma samples from 40 individuals. Participants were divided into five groups of eight individuals as follows: those dia­gnosed with glioblastoma, astrocytoma, oligodendroglioma, benign me­ningioma, and healthy controls. The study groups included 17 wo­men and 15 men, with a median age of 52,5 years. The control group in­cluded seven women and one man, with a median age of 53 years. Results . Plasma levels of miR-30c-5p, miR-128-3p, miR-186-5p, miR-194-5p, miR-484, miR-19b-3p, miR-431-5p, miR-3168, let-7c-5p, and miR-363-3p were determined using NGS data from 58 plasma samples (Gvaldin, 2024). The validation cohort revealed differential expression changes for four microRNAs (miR-128-3p, miR-194-5p, miR-19b-3p, and miR-363-3p) across the study groups. Conclusion . Differential expression of circulating miR-128-3p, miR-194-5p, miR-19b-3p, and miR-363-3p is associated with brain tumor oncogenesis and can be used for their diagnosis.

  • Machine learning models for brain tumors differential diagnosis

    by D.YU. Gvaldin, E.P. Omelchuk, N.A. Petrusenko, N.N. Timoshkina, E.E. Rostorguev, S.E. Kavitskiy, V.I. Voshedskii, M.N. Lesnoy

    The molecular profile of the tumor is crucial for classifying brain tumors and, consequently, for selecting the appropriate treatment strategy. Circulating microRNAs are considered promising biomarkers for tumors. MicroRNA NGS sequencing data can be effectively categorized using machine learning. Objective. To create a classifier model using machine learning algorithms for differential diagnosis of glial and benign brain tumors based on high-throughput sequencing data of a tumor-associated pattern of circulating microRNAs. Materials and methods. MicroRNAs isolated from plasma of patients with glioblastoma (n=22), astrocytoma (n=15), oligodendroglioma (n=5), meningioma (n=13), and control subjects (n=4) were analyzed using high-throughput sequencing on a MiSeq Dx instrument (Illumina, Inc., USA). Differential expression analysis was performed using the DESeq2 software package. For each study group of patients, differentially expressed microRNAs were selected that met the following criteria: |Log2FC|>1 and p<0.05. The sequencing data was normalized and supplemented with synthetic data to eliminate class imbalance, then divided into training and test sets in an 80:20 ratio. The random forest method and the XGBoost algorithm were selected for the machine learning. Results. Fifty-one differentially expressed tumor-specific microRNAs were identified: 17 in the group of patients with glioblastoma, 10 in the group of patients with astrocytoma, 10 in the group of patients with oligodendroglioma, and 14 in the group of patients with meningioma. With the test dataset, the accuracy of the models trained using the random forest method and the XGBoost algorithm was 85.2% (p<0.001) and 81.5% (p<0.001), respectively. During high-throughput sequencing, bioinformatic analysis, and machine learning methods, 10 microRNAs (hsa-miR-192-5p, hsa-miR-194-5p, hsa-miR-128-3p, hsa-miR-30c-5p, hsa-miR-186-5p, hsa-miR-340-5p, hsa-miR-3168, hsa-miR-19b-3p, hsa-miR-144-5p, hsa-let-7c-5p) were selected for the differential diagnosis of glial tumors and meningiomas. Conclusion. The selected tumor-specific microRNAs can serve as the basis for a minimally invasive diagnostic panel for brain tumors.


  • Open Access

    Creation of a plasma collection for the search of diagnostic biomarkers of glial tumors

    by E. P. Omelchuk, N. N. Timoshkina, D. Yu. Gvaldin, N. A. Petrusenko, E. E. Rostorguev, I. A. Novikova, O. I. Kit

    Aim. To create a collection of plasma samples of patients with brain tumors (BTs) for the development of a diagnostic microRNA (ribonucleic acid) panel of glial tumors.Material and methods. Plasma samples of patients with benign and malignant BTs were obtained by double centrifugation of whole blood and then frozen at -75оС.Fifty-nine RNA samples isolated from blood plasma were analyzed by next-generation sequencing (NGS).Results. Currently, the biobank contains samples from 339 patients with primary and secondary BTs and 10 control group individuals (698 samples — 2 plasma aliquots per individual), including 143 men and 206 women. The age of the patients ranged from 19 to 91 years (median — 56 years). Primary BTs (41%) included two following groups: benign (33,7%) and malignant (66,3%). Meningiomas constituted the bulk (91%) of the benign BTs. Among the malignant tumors, glioblastomas (46,7%) and astrocytomas (41,6%) prevailed, while oligodendrogliomas and ependymomas accounted for only 9,1 and 2,5%, respectively. Secondary BTs (59%) are represented by recurrent glial tumors (92,5%) and metastatic tumors (7,5%) of lung cancer (71,4%) and breast cancer (28.6%). A protocol for the primary preparation of liquid biopsy samples was implemented, which made it possible to obtain high-quality deoxyribonucleic acid libraries for the selected microRNA profiling platform.Conclusion. The creation of a plasma sample collection is the basis for searching circulating biomarkers of BTs.


  • Open Access

    Molecular genetic aspects of prostate cancer radioresistance

    by E. P. Omelchuk, D. S. Kutilin, S. N. Dimitriadi, М. А. Гусарева, N. N. Timoshkina

    Радиорезистентность рака предстательной железы представляет собой сложную терапевтическую проблему. После проведения лучевой терапии 22–69% больных раком предстательной железы сталкиваются с биохимическим рецидивом. Почти половина таких пациентов прогрессирует до клинического рецидива в течение 15 лет, а у трети наблюдается прогрессия до кастрационно-резистентного рака. Настоящий обзор посвящен анализу данных литературы о механизмах развития радиорезистентности в онкотрансформированных клетках предстательной железы. Осуществлен поиск литературных источников, опубликованных в базах eLibrary, PubMed, Scopus по ключевым словам: рак предстательной железы, радиорезистентность, маркеры. Всего найдено 568 иностранных и 178 отечественных работ, опубликованных в период 1975–2020 гг., из которых отобрано 77 статей, раскрывающих молекулярную основу радиорезистентности и вышедших в печать в 2001–2020 гг. Современные представления о происхождении устойчивых к радиации злокачественных клеток концентрируются на процессах, приводящих к усиленной репарации ДНК, активации антиапоптотических сигнальных путей, снижению уровня эндо- и экзогенных активных форм кислорода. Также немаловажную роль играют состояние микроокружения опухоли, аутофагия и эпителиально-мезенхимальный переход. Механизмы развития устойчивости к радиационному лечению на сегодняшний день объясняются наличием стволовых клеток опухоли, которые обусловливают генетическую гетерогенность и возможность ухода от воздействия терапии с помощью активации сигнальных путей канцерогенеза. Также опухоль может быть защищена от радиации гипоксической микросредой. Ввиду возникающей пластичности опухолевых стволовых клеток в ответ на лучевую терапию актуальным представляется поиск их маркеров с целью скрининга и идентификации радиорезистентного рака предстательной железы.


  • Open Access

    CURRENT VIEWS ON PREDICTORS AND BIOMARKERS OF EARLY DIAGNOSIS OF ANTHRACYCLINE-MEDIATED CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE)

    by O. I. Kit, Dmitry Yuryevich Gvaldin, E. P. Omelchuk, N. N. Timoshkina

    Anthracyclines are effectively used in many therapeutic regimens for breast cancer (BC). However, the dose-dependent cardiotoxic effect causes certain limitations on their use. Laboratory tests for risk prediction and early diagnosis of anthracycline-induced cardiotoxicity (ACIC) based on measuring the activity and concentration of topoisomerase 2β, the levels of troponins T and I (TnT и TnI), N-terminal fragment of brain natriuretic peptide progenitor, remain relevant, but complicate the risk stratification with low specificity. Recently, the number of works devoted to the study of new biomarkers ACIC has been growing: galectin-3, soluble ST-2 (sST-2), and myeloperoxidase (MPO). In this review we analyzed current understanding of the classical markers ACIC and the results of recent studies dedicated to new predictors.


  • Open Access

    GENES COPY NUMBER VARIATION INDEX AND RESISTANCE OF DIFFERENT NOSOLOGY TUMOR CELLS TO RADIATION

    by M.A. Gusareva, M.S. Zinkovich, N.G. Kosheleva, A.A. Solntseva, E.A. Karnaukhova, L.Y. Rozenko, N.B. Fatkina, D.S. Potemkin, E.P. Omelchuk, I.A. Udalenkova